NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Hoffmann-La Roche
Conditions: Off-Label Use
Interventions: Rituximab
Countries: France, Germany, Italy, Spain, United Kingdom
This study is to characterize the indications for which rituximab is being used and to evaluate the use of the Patient Alert Card (PAC) in participants receiving the medication for non-oncology conditions at infusion centers. The study involves the retrospective chart review of rituximab users' medical records in non-oncology indications as well as a survey to collect information on participant characteristics, and will include questions about participant knowledge on the risk of infections, participant receipt and review of the PAC, and any actions the participant has taken as a result of receiving the PAC.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * Participant is in the center to receive an infusion for rituximab for a non-oncology indication during the study period * Aged 18 years or older Exclusion Criteria: * Has previously already completed the rituximab survey * Has participated in the past 12 months in a clinical trial in which rituximab was one of the treatments being evaluated.
- Clermont-Ferrand, France
- Corbeil-Essonnes, France
- Le Mans, France
- Lille, France
- Montpellier, France
- Nantes, France
- Paris, France
- Pessac, France
- Saint-Etienne, France
- Toulouse, France
- Dresden, Germany
- Frankfurt, Germany
- Freiburg im Breisgau, Germany
- Halle, Germany
- Heidelberg, Germany
- Lübeck, Germany
- Mainz, Germany
- Ratingen, Germany
- Vogelsang-Gommern, Germany
- Ferrara, Emilia-Romagna, Italy
- Rome, Lazio, Italy
- Milan, Lombardy, Italy
- Milan, Lombardy, Italy
- Turin, Piedmont, Italy
- Cagliari, Sardinia, Italy
- Florence, Tuscany, Italy
- Pisa, Tuscany, Italy
- Siena, Tuscany, Italy
- Sabadell, Barcelona, Spain
- A Coruña, LA Coruña, Spain
- + 18 more on CT.gov